Aug 12, 2026 06:57AM
Jun 8, 2026 07:00AM
Jun 8, 2026 06:59AM
May 13, 2026 04:07PM
Apr 27, 2026 07:30AM
Apr 15, 2026 09:05AM
Apr 15, 2026 09:05AM Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
Mar 19, 2026 11:00AM
Mar 5, 2026 07:00AM
Jan 8, 2026 09:05AM
Jan 8, 2026 09:05AM
Jan 5, 2026 07:01AM
Jan 5, 2026 07:00AM
Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
Dec 12, 2025 10:47AM
Nov 4, 2025 09:00AM
Oct 23, 2025 07:00AM
Oct 23, 2025 07:00AM
Oct 6, 2025 07:00AM
Aug 5, 2025 07:00AM
Jun 27, 2025 07:03AM Tango Therapeutics (TNGX) Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lun
Jun 27, 2025 07:00AM
May 21, 2025 07:01AM
May 21, 2025 07:00AM
May 12, 2025 07:00AM
Apr 9, 2025 05:00AM
Feb 27, 2025 07:00AM
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Nov 6, 2024 07:02AM
Nov 6, 2024 07:00AM
Mar 18, 2024 07:00AM
Jan 3, 2024 07:00AM
Nov 8, 2023 07:00AM
Sep 6, 2023 07:06AM
Sep 6, 2023 07:00AM Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers
Aug 28, 2023 07:00AM
Aug 7, 2023 07:00AM
Jul 24, 2023 07:00AM
Jul 10, 2023 07:00AM
May 9, 2023 07:00AM
Apr 3, 2023 07:06AM
Apr 3, 2023 07:00AM Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers
Mar 27, 2023 07:00AM
Jan 25, 2023 07:00AM
Jan 25, 2023 07:00AM
Aug 10, 2022 07:00AM
May 11, 2022 07:00AM
Mar 28, 2022 07:00AM
Jan 24, 2022 07:01AM Tango Therapeutics, Inc (TNGX) Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates
Jan 24, 2022 07:00AM

330,179 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All